Metabolic & weight · Investigational peptide
Also known as AM833
A long-acting amylin analogue studied alone and with semaglutide. It is not an FDA-approved drug.[1]
Human studies are available in defined contexts, but the evidence remains product-, population-, route-, or outcome-specific.
Reviewed Jul 22, 2026 · U.S.-focused reference profile
Read the context, not only the compound name. Evidence and status can change with the form, route, population, and use. This profile does not assess individual suitability.
Orientation
Start with identity and research context. Similar names do not establish equivalent products or evidence.
Published research or product contexts. These are not personal indications.
Evidence can change with chemical form, formulation, route, ingredients, and manufacturing. A brand, salt, fragment, or cosmetic ingredient may not represent the same evidence.
What is known
Human studies are available in defined contexts, but the evidence remains product-, population-, route-, or outcome-specific. This is a description, not a rating or recommendation.
GLP-1, metabolic and weight-management
A randomized phase 2 trial and later phase 3 combination studies show human evidence for weight-related outcomes and describe frequent gastrointestinal adverse events. Evidence for a combination does not establish the independent effects or approval of cagrilintide alone.
Regulatory review is incomplete, long-term surveillance is unavailable, and results from cagrilintide-semaglutide combinations cannot be attributed entirely to cagrilintide. Trial findings do not make an investigational product equivalent to an approved medicine.
Preclinical amylin-receptor pharmacology supported development. Laboratory or animal findings do not establish individual benefit or safety in people.[1]
More human evidence does not automatically transfer to a different product, route, population, or purpose. Limited evidence does not prove no biological activity; it means the relevant clinical question is not established by the reviewed material.
What needs caution
Known published concerns and unanswered questions are kept separate so absence of evidence is never presented as reassurance.
Human trials report gastrointestinal adverse events and injection-site reactions. The complete long-term and rare-event profile is not established, and non-trial products introduce additional quality and identity risks.
Research or cosmetic products may add identity, strength, purity, sterility, contamination, or formulation concerns. This is separate from the evidence about the compound itself.Source [1]Regulatory review is incomplete, long-term surveillance is unavailable, and results from cagrilintide-semaglutide combinations cannot be attributed entirely to cagrilintide. Trial findings do not make an investigational product equivalent to an approved medicine.
Human outcomes, long-term safety, formulation identity, and product consistency remain limited or unresolved in the cited material.Source [1]Common effects, important warnings, product-quality concerns, and evidence gaps are different kinds of information. A risk in one product label may not apply to every formulation; an uncertainty proves neither safety nor harm.
Match the product
Form describes the specific product; route describes how it reaches the body. These are sourced descriptions, not instructions.
Clinical trials have studied subcutaneous formulations; no FDA-approved cagrilintide product is described here.
Routes shown apply only to the named published or investigational formulation; they are not instructions for use.
U.S. product context
The compound is being studied in research and has not been approved by the FDA as a medicine for routine marketing.
Status applies to a product, formulation, route, population, and use. It does not apply to a name in the abstract.
Cagrilintide remains an investigational drug studied in registered clinical trials. This profile does not identify an FDA-approved cagrilintide product.
Specific form or route not separately published in this record.View sourceTake it forward
Organize a conversation with a qualified professional without creating a treatment recommendation, dose, or protocol.
Trace the record
Each source supports the section that cites it; publication does not imply endorsement or suitability.
Cagrilintide phase 2 weight-management trial
Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a phase 2 trial. The Lancet. 2021.
The Lancet · Published Nov 16, 2021 · Accessed Jul 22, 2026 · Clinical study
Open sourceCagrilintide clinical trial record
ClinicalTrials.gov. NCT03856047: Investigation of efficacy and safety of cagrilintide in people with overweight or obesity.
U.S. National Library of Medicine · Published Nov 16, 2021 · Accessed Jul 22, 2026 · Reference source
Open sourceIdentity, human evidence, laboratory and animal findings, risks, uncertainty, and U.S. product status are shown separately. Missing information stays marked as unpublished instead of being inferred.
